753 844
[(Fig._1)TD$FIG]
(A)
Biopsy
Gleason
grade
Total
paƟents
at risk (
n
)
PaƟents
at risk at
1 yr (
n
)
CEs at
1 yr (
n
)
PaƟents
at risk at
5 yr (
n
)
CEs at
5 yr (
n
)
PaƟents
at risk at
10 yr (
n
)
CEs at
10 yr (
n
)
PaƟents
at risk at
15 yr (
n
)
CEs at
15 yr (
n
)
172
558
116
2121
38
4409
4
6456
6776
I (2–6)
87
67
72
396
31
988
4
1654
1773
II (3 + 4)
55
23
44
190
18
503
3
874
955
III (4 + 3)
92
31
73
141
42
362
1
600
636
IV (8)
68
14
59
68
32
195
3
350
389
V (9–10)
(B)
Biopsy
Gleason
grade
Total
paƟents
at risk (
n
)
PaƟents
at risk at
1 yr (
n
)
CEs at
1 yr (
n
)
PaƟents
at risk at
5 yr (
n
)
CEs at
5 yr (
n
)
PaƟents
at risk at
10 yr (
n
)
CEs at
10 yr (
n
)
PaƟents
at risk at
15 yr (
n
)
CEs at
15 yr (
n
)
108
538
94
2063
50
4346
5
6367
6722
I (2–6)
54
64
46
383
28
971
6
1607
1757
II (3 + 4)
31
22
29
184
21
479
10
840
943
III (4 + 3)
50
27
44
135
33
338
7
565
617
IV (8)
33
13
33
65
27
173
7
308
368
V (9–10)
Survival (%)
0
10
20
30
40
50
60
70
80
90
100
Time (yr)
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0
9-10
8
4+3
3+4
2-6
GS
Survival (%)
0
10
20
30
40
50
60
70
80
90
100
Time (yr)
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0
9-10
8
4+3
3+4
2-6
GS
Fig. 1 – Kaplan-Meier survival plots and tables with numbers of events and numbers of patients still at risk at each time point for (A) prostate cancer–
specific survival and (B) bone metastasis–free survival stratified by prognostic Gleason score category at biopsy. CE = cumulative events.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 5 0 – 7 5 9
753